Skip to main content
SpringerLink
Log in

PET-CT bei Lymphompatienten

PET/CT in lymphoma patients

  • PET-CT
  • Published:
Der Radiologe Aims and scope Submit manuscript

Zusammenfassung

Fragestellung

Erste Ergebnisse der PET-CT bei Morbus Hodgkin (HD) und den aggressiven Non-Hodgkin-Lymphomen (NHL) werden beschrieben.

Patienten und Methoden

Von März 2001 bis August 2004 wurden 822 PET-CT bei Lymphompatienten zum primären Staging, zum Restaging nach Therapie und zur Rezidivdiagnostik an unserer Klinik durchgeführt. Für die Koregistration wurde ein Low-dose-CT ohne i.v.-Kontrastmittel verwendet.

Ergebnisse

Durch die exakte anatomische Zuordnung der 18F-FDG aufnehmenden Läsionen wurden unklare oder falsch-positive PET-Befunde vermieden. Die PET-CT erzielte im Vergleich zur KM-verstärkten CT eine höhere Sensitivität und Spezifität bei Patienten mit HD und aggressiven NHL. Die Integration der PET-CT in die Planung der Strahlentherapie führte zu einer Optimierung der Feldgrenzen.

Schlussfolgerung

Die PET-CT hat sich bereits in der Phase der initialen klinischen Evaluation als wertvoll beim Staging und Restaging von Lymphomen erwiesen. Die exakte anatomische Zuordnung der PET-Informationen ist für eine sichere Befundung, für die Planung einer Strahlentherapie und die Planung einer Operation zur Biopsie unerlässlich.

Abstract

Purpose

First results of PET/CT in Hodgkin’s disease (HD) and aggressive non-Hodgkin’s lymphoma (NHL) are reported.

Patients and methods

From March 2001 to August 2004 822 PET/CT were performed at our clinic in lymphoma patients for primary staging, restaging after therapy, and diagnosis of recurrence. For coregistration non contrast-enhanced low-dose CT were used.

Results

Due to the exact anatomic localization of 18F-FDG accumulating lesions equivocal or false positive PET findings are avoided. In comparison to contrast enhanced CT, PET/CT has a higher sensitivity and specificity in patients with HD and aggressive NHL. Integration of PET/CT in treatment planning of radiation therapy optimizes the field volume.

Conclusion

Even in the initial phase of clinical evaluation, PET/CT has proven useful in staging and restaging of lymphoma. The exact anatomic localization of the PET findings is essential for a precise report, for treatment planning of radiation therapy, and for planning surgical biopsy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1a–p
Abb. 2a, b
Abb. 3a–j

Literatur

  1. Alavi A, Gupta N, Alberini JL et al. (2003) Positron tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 32:293–321

    Article  Google Scholar 

  2. Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L (1999) Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 38:799–804

    Article  CAS  PubMed  Google Scholar 

  3. Barrington SF, Maisey MN (1996) Skeletal muscle uptake of fluorine-18-FDG: effect of oral diazepam. J Nucl Med 37:1127–1129

    CAS  PubMed  Google Scholar 

  4. Bar-Shalom R, Yefremov N, Guralnik L et al. (2003) Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 44:1200–1209

    PubMed  Google Scholar 

  5. Chandar S, Meltzer CC, McCook BM (2002) Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography. Clin Nucl Med 27:22–24

    Article  PubMed  Google Scholar 

  6. Ciernik IF, Dizendorf E, Baumert B et al. (2003) Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys 57:853–863

    Article  PubMed  Google Scholar 

  7. Cook GJ, Fogelman I, Maisey MN (1996) Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 26:308–314

    CAS  PubMed  Google Scholar 

  8. Dizendorf EV, Baumert BG, von Schulthess GK, Lütolf UM, Steinert HC (2003) Impact of whole-body18F-FDG PET on staging and management patients for radiation therapy. J Nucl Med 44:23–29

    Google Scholar 

  9. Engel H, Steinert H, Buck A, von Schulthess GK (1996) Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 37:441–446

    CAS  PubMed  Google Scholar 

  10. Fayad LM, Cohade C, Wahl RL, Fishman EK (2003) Sacral fractures: a potential pitfall of FDG positron emission tomography. AJR 181:1239–1243

    PubMed  Google Scholar 

  11. Gambhir SS, Czernin J, Schwimmer J, Silvermam DH, Coleman RE, Phelps ME (2000) A tabulated summary of the FDG PET literature. J Nucl Med 42:1S–93S

    Google Scholar 

  12. Glatz S, Kotzerke J, Moog F, Sandherr M, Heimpel H, Reske S (1996) Vortäuschung eines mediastinalen Non-Hodgkin-Lymphomrezidivs durch diffuse Thymushyperplasie im18F-FDG-PET. Fortschr Röntgenstr 165:309–310

    Google Scholar 

  13. Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von Schulthess GK (2002) Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging 29:1393–1398

    Article  PubMed  Google Scholar 

  14. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess (2002) PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 225:575–581

    PubMed  Google Scholar 

  15. Hoegerle S, Juengling F, Otte A, Altehoefer C, Moser EA, Nitzsche EU (1998) Combined FDG and [F-18]fluoride whole-body PET: a feasible two-in-one approach to cancer imaging? Radiology 209:253–258

    CAS  PubMed  Google Scholar 

  16. Hoffmann E, Kletter K, Diemling M, Becherer A, Pfeffel F, Petkov V (1999) Positron emission tomography with fluorine-18–2-fluoro-2-deoxy-D-glucose (F-18-FDG) does not visualise extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 10:1185–1189

    Article  CAS  PubMed  Google Scholar 

  17. Hueltenschmidt B, Sautter-Bihl ML, Lang O et al. (2001) Whole body positron emission tomography in the treatment of Hodgkin’s disease. Cancer 91:302–310

    Article  CAS  PubMed  Google Scholar 

  18. Jacobsson H, Celsing F, Ingvar M, Stone-Elander S, Larsson SA (1998) Accumulation of FDG in axillary sweat glands in hyperhidrosis: a pitfall in whole-body PET examination. Eur Radiol 8:482–483

    Article  CAS  PubMed  Google Scholar 

  19. Kamel EM, Goerres GW, Burger C, von Schulthess GK, Steinert HC (2002) Recurrent laryngeal nerve palsy in patients with lung cancer: detection with PET-CT image fusion—report of six cases. Radiology 224:153–156

    PubMed  Google Scholar 

  20. Reske SN, Kotzerke J (2001) FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, „Onko-PET III“. Eur J Nucl Med 28:1707–1723

    Article  CAS  PubMed  Google Scholar 

  21. Reske SN (2003) PET and restaging of malignant lymphoma including residual masses and relapse. Eur J Nucl Med Mol Imaging 30 [suppl 1]:S89–S96

    Google Scholar 

  22. Schaefer NG, Hany TF, Taverna C, Stumpe KDM, von Schulthess GK, Goerres GW (2004) Coregistered18F-fluorodeoxyglucose positron emission tomography and computed tomography (PET/CT) in patients with aggressive non-Hodgkin lymphoma and Hodgkin’s disease: do we need contrast-enhanced CT? Radiology 232:823–829

    PubMed  Google Scholar 

  23. Schiepers C, Filmont J-E, Czernin J (2003) PET for staging of Hodgkin’s disease and non-Hodgkin’s lymphoma. Eur J Nucl Med Mol Imaging 30 [suppl 1]:S89–S96

  24. Schöder H, Larson SM, Yeung HWD (2004) PET/CT in oncology—integration into clinical management of lymphoma, melanoma and gastrointestinal malignancies. J Nucl Med 45:72S–81S

    PubMed  Google Scholar 

  25. Spaepen K, Stroobants S, Verhoef G, Mortelmans L (2003) Positron emission tomography with [18F]FDG for therapy response monitoring in lymphoma patients. Eur J Nucl Med Mol Imaging 30 [suppl 1]:S97–S105

  26. Stumpe KD, Urbinelli M, Steinert HC et al. (1998) Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 25:721–728

    Article  CAS  PubMed  Google Scholar 

  27. Tatlidil R, Jadvar H, Bading JR, Conti PS (2002) Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology 224:783–787

    PubMed  Google Scholar 

  28. Tasumi M, Cohade C, Nakamoto Y, Wahl RL (2003) Fluorodeoxyglucose uptake in the aortic wall at PET/CT: a possible finding for active atherosclerosis. Radiology 229:831–837

    PubMed  Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Nuklearmedizin, Universitätsspital Zürich, Schweiz

    H. C. Steinert

  2. Klinik und Poliklinik für Nuklearmedizin, Universitätsspital, Rämistraße 100, 8091, Zürich, Schweiz

    H. C. Steinert

Authors
  1. H. C. Steinert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. C. Steinert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Steinert, H.C. PET-CT bei Lymphompatienten. Radiologe 44, 1060–1067 (2004). https://doi.org/10.1007/s00117-004-1121-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00117-004-1121-x

Schlüsselwörter

Keywords

Search

Navigation